Global Vasculitis Drug Market Growth 2025-2031

October 2025 | 103 pages | ID: G02A7CE14898EN
LP Information

Abstracts

The global Vasculitis Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the ?Vasculitis Drug Industry Forecast? looks at past sales and reviews total world Vasculitis Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Vasculitis Drug sales for 2025 through 2031. With Vasculitis Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Vasculitis Drug industry.

This Insight Report provides a comprehensive analysis of the global Vasculitis Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Vasculitis Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Vasculitis Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Vasculitis Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Vasculitis Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Vasculitis Drug market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• Blisibimod
• CCX-168
• Gevokizumab
• Rituximab Biosimilar
• Others

Segmentation by Application:

• Polyarteritis Nodosa
• Thrombotic Vasculitis
• Granulomatous Vasculitis
• Lymphocytic Vasculitis
• Others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Merck
• Bayer
• Farmalider
• Hainan Pharmaceutical Factory
• Shanghaihuangxiang Lantian Pharmaceutical
• Huzhou Konch Pharmaceutical
• CSPC Ouyi Pharmaceutical
• Sino-US Zibo Xinhua-Perrigo Pharmaceutical
• Hubei Biocause Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Vasculitis Drug market?
What factors are driving Vasculitis Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Vasculitis Drug market opportunities vary by end market size?
How does Vasculitis Drug break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Vasculitis Drug Annual Sales 2020-2031
  2.1.2 World Current & Future Analysis for Vasculitis Drug by Geographic Region, 2020, 2024 & 2031
  2.1.3 World Current & Future Analysis for Vasculitis Drug by Country/Region, 2020, 2024 & 2031
2.2 Vasculitis Drug Segment by Type
  2.2.1 Blisibimod
  2.2.2 CCX-168
  2.2.3 Gevokizumab
  2.2.4 Rituximab Biosimilar
  2.2.5 Others
2.3 Vasculitis Drug Sales by Type
  2.3.1 Global Vasculitis Drug Sales Market Share by Type (2020-2025)
  2.3.2 Global Vasculitis Drug Revenue and Market Share by Type (2020-2025)
  2.3.3 Global Vasculitis Drug Sale Price by Type (2020-2025)
2.4 Vasculitis Drug Segment by Application
  2.4.1 Polyarteritis Nodosa
  2.4.2 Thrombotic Vasculitis
  2.4.3 Granulomatous Vasculitis
  2.4.4 Lymphocytic Vasculitis
  2.4.5 Others
2.5 Vasculitis Drug Sales by Application
  2.5.1 Global Vasculitis Drug Sale Market Share by Application (2020-2025)
  2.5.2 Global Vasculitis Drug Revenue and Market Share by Application (2020-2025)
  2.5.3 Global Vasculitis Drug Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Vasculitis Drug Breakdown Data by Company
  3.1.1 Global Vasculitis Drug Annual Sales by Company (2020-2025)
  3.1.2 Global Vasculitis Drug Sales Market Share by Company (2020-2025)
3.2 Global Vasculitis Drug Annual Revenue by Company (2020-2025)
  3.2.1 Global Vasculitis Drug Revenue by Company (2020-2025)
  3.2.2 Global Vasculitis Drug Revenue Market Share by Company (2020-2025)
3.3 Global Vasculitis Drug Sale Price by Company
3.4 Key Manufacturers Vasculitis Drug Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Vasculitis Drug Product Location Distribution
  3.4.2 Players Vasculitis Drug Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR VASCULITIS DRUG BY GEOGRAPHIC REGION

4.1 World Historic Vasculitis Drug Market Size by Geographic Region (2020-2025)
  4.1.1 Global Vasculitis Drug Annual Sales by Geographic Region (2020-2025)
  4.1.2 Global Vasculitis Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Vasculitis Drug Market Size by Country/Region (2020-2025)
  4.2.1 Global Vasculitis Drug Annual Sales by Country/Region (2020-2025)
  4.2.2 Global Vasculitis Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Vasculitis Drug Sales Growth
4.4 APAC Vasculitis Drug Sales Growth
4.5 Europe Vasculitis Drug Sales Growth
4.6 Middle East & Africa Vasculitis Drug Sales Growth

5 AMERICAS

5.1 Americas Vasculitis Drug Sales by Country
  5.1.1 Americas Vasculitis Drug Sales by Country (2020-2025)
  5.1.2 Americas Vasculitis Drug Revenue by Country (2020-2025)
5.2 Americas Vasculitis Drug Sales by Type (2020-2025)
5.3 Americas Vasculitis Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Vasculitis Drug Sales by Region
  6.1.1 APAC Vasculitis Drug Sales by Region (2020-2025)
  6.1.2 APAC Vasculitis Drug Revenue by Region (2020-2025)
6.2 APAC Vasculitis Drug Sales by Type (2020-2025)
6.3 APAC Vasculitis Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Vasculitis Drug by Country
  7.1.1 Europe Vasculitis Drug Sales by Country (2020-2025)
  7.1.2 Europe Vasculitis Drug Revenue by Country (2020-2025)
7.2 Europe Vasculitis Drug Sales by Type (2020-2025)
7.3 Europe Vasculitis Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Vasculitis Drug by Country
  8.1.1 Middle East & Africa Vasculitis Drug Sales by Country (2020-2025)
  8.1.2 Middle East & Africa Vasculitis Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Vasculitis Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Vasculitis Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Vasculitis Drug
10.3 Manufacturing Process Analysis of Vasculitis Drug
10.4 Industry Chain Structure of Vasculitis Drug

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Vasculitis Drug Distributors
11.3 Vasculitis Drug Customer

12 WORLD FORECAST REVIEW FOR VASCULITIS DRUG BY GEOGRAPHIC REGION

12.1 Global Vasculitis Drug Market Size Forecast by Region
  12.1.1 Global Vasculitis Drug Forecast by Region (2026-2031)
  12.1.2 Global Vasculitis Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Vasculitis Drug Forecast by Type (2026-2031)
12.7 Global Vasculitis Drug Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Merck
  13.1.1 Merck Company Information
  13.1.2 Merck Vasculitis Drug Product Portfolios and Specifications
  13.1.3 Merck Vasculitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.1.4 Merck Main Business Overview
  13.1.5 Merck Latest Developments
13.2 Bayer
  13.2.1 Bayer Company Information
  13.2.2 Bayer Vasculitis Drug Product Portfolios and Specifications
  13.2.3 Bayer Vasculitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.2.4 Bayer Main Business Overview
  13.2.5 Bayer Latest Developments
13.3 Farmalider
  13.3.1 Farmalider Company Information
  13.3.2 Farmalider Vasculitis Drug Product Portfolios and Specifications
  13.3.3 Farmalider Vasculitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.3.4 Farmalider Main Business Overview
  13.3.5 Farmalider Latest Developments
13.4 Hainan Pharmaceutical Factory
  13.4.1 Hainan Pharmaceutical Factory Company Information
  13.4.2 Hainan Pharmaceutical Factory Vasculitis Drug Product Portfolios and Specifications
  13.4.3 Hainan Pharmaceutical Factory Vasculitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.4.4 Hainan Pharmaceutical Factory Main Business Overview
  13.4.5 Hainan Pharmaceutical Factory Latest Developments
13.5 Shanghaihuangxiang Lantian Pharmaceutical
  13.5.1 Shanghaihuangxiang Lantian Pharmaceutical Company Information
  13.5.2 Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Product Portfolios and Specifications
  13.5.3 Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.5.4 Shanghaihuangxiang Lantian Pharmaceutical Main Business Overview
  13.5.5 Shanghaihuangxiang Lantian Pharmaceutical Latest Developments
13.6 Huzhou Konch Pharmaceutical
  13.6.1 Huzhou Konch Pharmaceutical Company Information
  13.6.2 Huzhou Konch Pharmaceutical Vasculitis Drug Product Portfolios and Specifications
  13.6.3 Huzhou Konch Pharmaceutical Vasculitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.6.4 Huzhou Konch Pharmaceutical Main Business Overview
  13.6.5 Huzhou Konch Pharmaceutical Latest Developments
13.7 CSPC Ouyi Pharmaceutical
  13.7.1 CSPC Ouyi Pharmaceutical Company Information
  13.7.2 CSPC Ouyi Pharmaceutical Vasculitis Drug Product Portfolios and Specifications
  13.7.3 CSPC Ouyi Pharmaceutical Vasculitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.7.4 CSPC Ouyi Pharmaceutical Main Business Overview
  13.7.5 CSPC Ouyi Pharmaceutical Latest Developments
13.8 Sino-US Zibo Xinhua-Perrigo Pharmaceutical
  13.8.1 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Company Information
  13.8.2 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Product Portfolios and Specifications
  13.8.3 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.8.4 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Main Business Overview
  13.8.5 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Latest Developments
13.9 Hubei Biocause Pharmaceutical
  13.9.1 Hubei Biocause Pharmaceutical Company Information
  13.9.2 Hubei Biocause Pharmaceutical Vasculitis Drug Product Portfolios and Specifications
  13.9.3 Hubei Biocause Pharmaceutical Vasculitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.9.4 Hubei Biocause Pharmaceutical Main Business Overview
  13.9.5 Hubei Biocause Pharmaceutical Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Vasculitis Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Vasculitis Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Blisibimod
Table 4. Major Players of CCX-168
Table 5. Major Players of Gevokizumab
Table 6. Major Players of Rituximab Biosimilar
Table 7. Major Players of Others
Table 8. Global Vasculitis Drug Sales by Type (2020-2025) & (K Pcs)
Table 9. Global Vasculitis Drug Sales Market Share by Type (2020-2025)
Table 10. Global Vasculitis Drug Revenue by Type (2020-2025) & ($ million)
Table 11. Global Vasculitis Drug Revenue Market Share by Type (2020-2025)
Table 12. Global Vasculitis Drug Sale Price by Type (2020-2025) & (USD/Pcs)
Table 13. Global Vasculitis Drug Sale by Application (2020-2025) & (K Pcs)
Table 14. Global Vasculitis Drug Sale Market Share by Application (2020-2025)
Table 15. Global Vasculitis Drug Revenue by Application (2020-2025) & ($ million)
Table 16. Global Vasculitis Drug Revenue Market Share by Application (2020-2025)
Table 17. Global Vasculitis Drug Sale Price by Application (2020-2025) & (USD/Pcs)
Table 18. Global Vasculitis Drug Sales by Company (2020-2025) & (K Pcs)
Table 19. Global Vasculitis Drug Sales Market Share by Company (2020-2025)
Table 20. Global Vasculitis Drug Revenue by Company (2020-2025) & ($ millions)
Table 21. Global Vasculitis Drug Revenue Market Share by Company (2020-2025)
Table 22. Global Vasculitis Drug Sale Price by Company (2020-2025) & (USD/Pcs)
Table 23. Key Manufacturers Vasculitis Drug Producing Area Distribution and Sales Area
Table 24. Players Vasculitis Drug Products Offered
Table 25. Vasculitis Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Vasculitis Drug Sales by Geographic Region (2020-2025) & (K Pcs)
Table 29. Global Vasculitis Drug Sales Market Share Geographic Region (2020-2025)
Table 30. Global Vasculitis Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 31. Global Vasculitis Drug Revenue Market Share by Geographic Region (2020-2025)
Table 32. Global Vasculitis Drug Sales by Country/Region (2020-2025) & (K Pcs)
Table 33. Global Vasculitis Drug Sales Market Share by Country/Region (2020-2025)
Table 34. Global Vasculitis Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 35. Global Vasculitis Drug Revenue Market Share by Country/Region (2020-2025)
Table 36. Americas Vasculitis Drug Sales by Country (2020-2025) & (K Pcs)
Table 37. Americas Vasculitis Drug Sales Market Share by Country (2020-2025)
Table 38. Americas Vasculitis Drug Revenue by Country (2020-2025) & ($ millions)
Table 39. Americas Vasculitis Drug Sales by Type (2020-2025) & (K Pcs)
Table 40. Americas Vasculitis Drug Sales by Application (2020-2025) & (K Pcs)
Table 41. APAC Vasculitis Drug Sales by Region (2020-2025) & (K Pcs)
Table 42. APAC Vasculitis Drug Sales Market Share by Region (2020-2025)
Table 43. APAC Vasculitis Drug Revenue by Region (2020-2025) & ($ millions)
Table 44. APAC Vasculitis Drug Sales by Type (2020-2025) & (K Pcs)
Table 45. APAC Vasculitis Drug Sales by Application (2020-2025) & (K Pcs)
Table 46. Europe Vasculitis Drug Sales by Country (2020-2025) & (K Pcs)
Table 47. Europe Vasculitis Drug Revenue by Country (2020-2025) & ($ millions)
Table 48. Europe Vasculitis Drug Sales by Type (2020-2025) & (K Pcs)
Table 49. Europe Vasculitis Drug Sales by Application (2020-2025) & (K Pcs)
Table 50. Middle East & Africa Vasculitis Drug Sales by Country (2020-2025) & (K Pcs)
Table 51. Middle East & Africa Vasculitis Drug Revenue Market Share by Country (2020-2025)
Table 52. Middle East & Africa Vasculitis Drug Sales by Type (2020-2025) & (K Pcs)
Table 53. Middle East & Africa Vasculitis Drug Sales by Application (2020-2025) & (K Pcs)
Table 54. Key Market Drivers & Growth Opportunities of Vasculitis Drug
Table 55. Key Market Challenges & Risks of Vasculitis Drug
Table 56. Key Industry Trends of Vasculitis Drug
Table 57. Vasculitis Drug Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Vasculitis Drug Distributors List
Table 60. Vasculitis Drug Customer List
Table 61. Global Vasculitis Drug Sales Forecast by Region (2026-2031) & (K Pcs)
Table 62. Global Vasculitis Drug Revenue Forecast by Region (2026-2031) & ($ millions)
Table 63. Americas Vasculitis Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 64. Americas Vasculitis Drug Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 65. APAC Vasculitis Drug Sales Forecast by Region (2026-2031) & (K Pcs)
Table 66. APAC Vasculitis Drug Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 67. Europe Vasculitis Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 68. Europe Vasculitis Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Middle East & Africa Vasculitis Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 70. Middle East & Africa Vasculitis Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 71. Global Vasculitis Drug Sales Forecast by Type (2026-2031) & (K Pcs)
Table 72. Global Vasculitis Drug Revenue Forecast by Type (2026-2031) & ($ millions)
Table 73. Global Vasculitis Drug Sales Forecast by Application (2026-2031) & (K Pcs)
Table 74. Global Vasculitis Drug Revenue Forecast by Application (2026-2031) & ($ millions)
Table 75. Merck Basic Information, Vasculitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 76. Merck Vasculitis Drug Product Portfolios and Specifications
Table 77. Merck Vasculitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 78. Merck Main Business
Table 79. Merck Latest Developments
Table 80. Bayer Basic Information, Vasculitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 81. Bayer Vasculitis Drug Product Portfolios and Specifications
Table 82. Bayer Vasculitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 83. Bayer Main Business
Table 84. Bayer Latest Developments
Table 85. Farmalider Basic Information, Vasculitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 86. Farmalider Vasculitis Drug Product Portfolios and Specifications
Table 87. Farmalider Vasculitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 88. Farmalider Main Business
Table 89. Farmalider Latest Developments
Table 90. Hainan Pharmaceutical Factory Basic Information, Vasculitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 91. Hainan Pharmaceutical Factory Vasculitis Drug Product Portfolios and Specifications
Table 92. Hainan Pharmaceutical Factory Vasculitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 93. Hainan Pharmaceutical Factory Main Business
Table 94. Hainan Pharmaceutical Factory Latest Developments
Table 95. Shanghaihuangxiang Lantian Pharmaceutical Basic Information, Vasculitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 96. Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Product Portfolios and Specifications
Table 97. Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 98. Shanghaihuangxiang Lantian Pharmaceutical Main Business
Table 99. Shanghaihuangxiang Lantian Pharmaceutical Latest Developments
Table 100. Huzhou Konch Pharmaceutical Basic Information, Vasculitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 101. Huzhou Konch Pharmaceutical Vasculitis Drug Product Portfolios and Specifications
Table 102. Huzhou Konch Pharmaceutical Vasculitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 103. Huzhou Konch Pharmaceutical Main Business
Table 104. Huzhou Konch Pharmaceutical Latest Developments
Table 105. CSPC Ouyi Pharmaceutical Basic Information, Vasculitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 106. CSPC Ouyi Pharmaceutical Vasculitis Drug Product Portfolios and Specifications
Table 107. CSPC Ouyi Pharmaceutical Vasculitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 108. CSPC Ouyi Pharmaceutical Main Business
Table 109. CSPC Ouyi Pharmaceutical Latest Developments
Table 110. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Basic Information, Vasculitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 111. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Product Portfolios and Specifications
Table 112. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 113. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Main Business
Table 114. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Latest Developments
Table 115. Hubei Biocause Pharmaceutical Basic Information, Vasculitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 116. Hubei Biocause Pharmaceutical Vasculitis Drug Product Portfolios and Specifications
Table 117. Hubei Biocause Pharmaceutical Vasculitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 118. Hubei Biocause Pharmaceutical Main Business
Table 119. Hubei Biocause Pharmaceutical Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Vasculitis Drug
Figure 2. Vasculitis Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Vasculitis Drug Sales Growth Rate 2020-2031 (K Pcs)
Figure 7. Global Vasculitis Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Vasculitis Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Vasculitis Drug Sales Market Share by Country/Region (2024)
Figure 10. Vasculitis Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Blisibimod
Figure 12. Product Picture of CCX-168
Figure 13. Product Picture of Gevokizumab
Figure 14. Product Picture of Rituximab Biosimilar
Figure 15. Product Picture of Others
Figure 16. Global Vasculitis Drug Sales Market Share by Type in 2025
Figure 17. Global Vasculitis Drug Revenue Market Share by Type (2020-2025)
Figure 18. Vasculitis Drug Consumed in Polyarteritis Nodosa
Figure 19. Global Vasculitis Drug Market: Polyarteritis Nodosa (2020-2025) & (K Pcs)
Figure 20. Vasculitis Drug Consumed in Thrombotic Vasculitis
Figure 21. Global Vasculitis Drug Market: Thrombotic Vasculitis (2020-2025) & (K Pcs)
Figure 22. Vasculitis Drug Consumed in Granulomatous Vasculitis
Figure 23. Global Vasculitis Drug Market: Granulomatous Vasculitis (2020-2025) & (K Pcs)
Figure 24. Vasculitis Drug Consumed in Lymphocytic Vasculitis
Figure 25. Global Vasculitis Drug Market: Lymphocytic Vasculitis (2020-2025) & (K Pcs)
Figure 26. Vasculitis Drug Consumed in Others
Figure 27. Global Vasculitis Drug Market: Others (2020-2025) & (K Pcs)
Figure 28. Global Vasculitis Drug Sale Market Share by Application (2024)
Figure 29. Global Vasculitis Drug Revenue Market Share by Application in 2025
Figure 30. Vasculitis Drug Sales by Company in 2025 (K Pcs)
Figure 31. Global Vasculitis Drug Sales Market Share by Company in 2025
Figure 32. Vasculitis Drug Revenue by Company in 2025 ($ millions)
Figure 33. Global Vasculitis Drug Revenue Market Share by Company in 2025
Figure 34. Global Vasculitis Drug Sales Market Share by Geographic Region (2020-2025)
Figure 35. Global Vasculitis Drug Revenue Market Share by Geographic Region in 2025
Figure 36. Americas Vasculitis Drug Sales 2020-2025 (K Pcs)
Figure 37. Americas Vasculitis Drug Revenue 2020-2025 ($ millions)
Figure 38. APAC Vasculitis Drug Sales 2020-2025 (K Pcs)
Figure 39. APAC Vasculitis Drug Revenue 2020-2025 ($ millions)
Figure 40. Europe Vasculitis Drug Sales 2020-2025 (K Pcs)
Figure 41. Europe Vasculitis Drug Revenue 2020-2025 ($ millions)
Figure 42. Middle East & Africa Vasculitis Drug Sales 2020-2025 (K Pcs)
Figure 43. Middle East & Africa Vasculitis Drug Revenue 2020-2025 ($ millions)
Figure 44. Americas Vasculitis Drug Sales Market Share by Country in 2025
Figure 45. Americas Vasculitis Drug Revenue Market Share by Country (2020-2025)
Figure 46. Americas Vasculitis Drug Sales Market Share by Type (2020-2025)
Figure 47. Americas Vasculitis Drug Sales Market Share by Application (2020-2025)
Figure 48. United States Vasculitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 49. Canada Vasculitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 50. Mexico Vasculitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 51. Brazil Vasculitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 52. APAC Vasculitis Drug Sales Market Share by Region in 2025
Figure 53. APAC Vasculitis Drug Revenue Market Share by Region (2020-2025)
Figure 54. APAC Vasculitis Drug Sales Market Share by Type (2020-2025)
Figure 55. APAC Vasculitis Drug Sales Market Share by Application (2020-2025)
Figure 56. China Vasculitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 57. Japan Vasculitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 58. South Korea Vasculitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 59. Southeast Asia Vasculitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 60. India Vasculitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 61. Australia Vasculitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 62. China Taiwan Vasculitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 63. Europe Vasculitis Drug Sales Market Share by Country in 2025
Figure 64. Europe Vasculitis Drug Revenue Market Share by Country (2020-2025)
Figure 65. Europe Vasculitis Drug Sales Market Share by Type (2020-2025)
Figure 66. Europe Vasculitis Drug Sales Market Share by Application (2020-2025)
Figure 67. Germany Vasculitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 68. France Vasculitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 69. UK Vasculitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 70. Italy Vasculitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 71. Russia Vasculitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 72. Middle East & Africa Vasculitis Drug Sales Market Share by Country (2020-2025)
Figure 73. Middle East & Africa Vasculitis Drug Sales Market Share by Type (2020-2025)
Figure 74. Middle East & Africa Vasculitis Drug Sales Market Share by Application (2020-2025)
Figure 75. Egypt Vasculitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 76. South Africa Vasculitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 77. Israel Vasculitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 78. Turkey Vasculitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 79. GCC Countries Vasculitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 80. Manufacturing Cost Structure Analysis of Vasculitis Drug in 2025
Figure 81. Manufacturing Process Analysis of Vasculitis Drug
Figure 82. Industry Chain Structure of Vasculitis Drug
Figure 83. Channels of Distribution
Figure 84. Global Vasculitis Drug Sales Market Forecast by Region (2026-2031)
Figure 85. Global Vasculitis Drug Revenue Market Share Forecast by Region (2026-2031)
Figure 86. Global Vasculitis Drug Sales Market Share Forecast by Type (2026-2031)
Figure 87. Global Vasculitis Drug Revenue Market Share Forecast by Type (2026-2031)
Figure 88. Global Vasculitis Drug Sales Market Share Forecast by Application (2026-2031)
Figure 89. Global Vasculitis Drug Revenue Market Share Forecast by Application (2026-2031)